百时美施贵宝：为增长而建——第44届摩根大通医疗健康年会

44thAnnual J.P. MorganHealthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO ForwardLooking Statements This presentation (as well as the oral statements made with respect to the information contained in this presentation) containsstatements about Bristol-Myers SquibbCompany’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constituteforward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are notstatements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by,these statements as a result of various factors, including, but not limited to: (i) new laws, government actions and regulations, including with respect to pricingcontrols and market access and the imposition of new tariffs, trade restrictions and export regulations, including the potentialfor international reference pricing andmost-favored nation drug pricing for our products, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectualproperty rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelinesorat all, (iv) difficulties or delays in thedevelopment and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi)adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii)political and financial instability, including changes in general economic conditions. These and other important factors arediscussed in the Company’s most recentannual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and ExchangeCommission’s website, on theCompany’s website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed. In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law,the Company undertakes no obligation to publicly update any of the provided information, whetheras a result ofnew information, future events, changedcircumstances or otherwise. Our goalis to build a companythat isfinanciallystrongand deliversindustry-leadingsustainable growth intothe 2030s and beyond Strong execution supports long-term growth objective 2025 Highlights Implemented furtherproductivity programsand scaled AI todelivercost savings andreinvestfor growth Advancedkey pipelineprogramsin life threateningconditions Completedstrategic businessdevelopmenttoenhance GrowthPortfolio IncreasedGrowth Portfoliosales by 17%*with4 assets thatannualized>$1B** Strengthenedbalance sheetby generatingstrong operatingcash flow GrowthPortfoliomomentum,strategicbusinessdevelopment, andpipeline advancementsstrengthenfoundation for long-term growth Pipeline assets each with multi-billion-dollar potential Significant data expected in 2026…and beyond NME registrational data LCM pivotal data Key next wave early-stage data 2026 2026 2026 •AdmilparantIPF(ALOFT-IPF)•Arlo-cel4L+ MM(QUINTESSENTIAL)•IberdomideRRMMPFS (EXCALIBER-RRMM)•MezigdomideRRMM(SUCCESSOR-2)•MilvexianAF(LIBREXIA-AF1)•MilvexianSSP(LIBEXIA-STROKE1)•RYZ1012L+ GEP-NETs(ACTION-1) •CobenfyAD Psychosis(ADEPT-1, 2 & 4)•SotyktuSLE(POETYK SLE-1 & 2) •BCMAxGPRC5D dual-targeting CAR TRRMM•Golcadomide1L FL(GOLSEEK-2)•MYK-224HFpEF(AURORA)•PumitamigSolid Tumors2•Zola-celAutoimmune Diseases(Breakfree-1 & 2) 2027 •AdmilparantPPF(ALOFT-PPF)•CobenfyBipolar-I(BALSAM-1 & 2)•MezigdomideRRMM(SUCCESSOR-1)•Reblozyl1L NTD MDS Associated Anemia(ELEMENT)•SotyktuSjogren’sSyndrome(POETYK SjS-1) 2027 •Anti-MTBR-tauAlzheimer’s Disease(TargetTau-1)•FAAH/MAGLAD Agitation(BALANCE-AAD-1)•FAAH/MAGLMS Spasticity(BALANCE-MSS-1) 2027 •AR LDDmCRPC(rechARge) 2028 2028 •Arlo-cel2-4L MM(QUINTESSENTIAL-2)•CobenfyAD Agitation(ADAGIO-2)•CobenfyAD Cognition(MINDSET-1 & 2)•CobenfyAdjunctive Bipolar-1(BALSAM-4)•Golcadomide2L+ FL(GOLSEEK-4)•Iza-brenEGFRm NSCLC(IZABRIGHT-Lung01)•Krazati1L NSCLC PD-L1 ≥50%(KRYSTAL-7) •Atigotatug+ nivolumab1L ES-SCLC(TIGOS)•GolcadomideHigh-Risk 1L LBCL(GOLSEEK-1)•Iza-bren1L TNBC(IZABRIGHT-Breast01)•Pumitamig1L ES-SCLC(ROSETTA-Lung-012)•Zola-celSLE(Breakfree-SLE) Drives wave of 10+ new product launch opportunities by 2030 R&D focused on rigorous execution to deliver high valueopportunities Value Science Execution •Ensuring each study has thehighest probability of success •Pursuing high impact medicinesto advance standards of care •Allocating resources toopportunities with thehighest probability of success•Deliverin